Genmab’s Recent Financial Developments
Genmab A/S, a prominent biopharmaceutical company, has taken a significant step by announcing a private offering of $1.5 billion in senior secured notes and $1.0 billion in senior unsecured notes. This move is part of its ongoing strategy to bolster its financial resources for future growth.
Details on the Notes Offering
The offering includes 6.250% senior secured notes due by 2032, alongside 7.250% senior unsecured notes maturing in 2033. With an issue price set at 100%, the offering is keenly anticipated to close soon, contingent on meeting standard closing conditions.
Purpose of the Offerings
The capital raised from the notes will be instrumental in financing Genmab's upcoming acquisition of Merus N.V., as well as covering associated fees and costs. This strategic acquisition is poised to enhance Genmab's capabilities and product offerings in the biopharmaceutical sector.
Secured and Unsecured Structures
Before the completion of the acquisition, these notes will be backed by segregated accounts housing the gross proceeds. After purchasing Merus common shares, the senior secured notes will become critically secured by a first-priority interest in select assets of Genmab and its subsidiaries, ensuring robust backing for the New Credit Facilities.
General Terms and Covenants
The indentures for the notes are expected to incorporate customary covenants. These covenants will impose certain restrictions on Genmab and its subsidiaries regarding incurring additional debts, paying dividends, and other financial maneuvers, maintaining a responsible fiscal approach amidst expansion.
Investor Considerations
It's important to note that the notes are unregistered under the Securities Act and are only available to qualified institutional buyers or non-U.S. entities in compliance with applicable regulations. This offering is solely made through an offering memorandum, ensuring clarity and transparency for potential investors.
Contact Information
For media inquiries, Genmab encourages reaching out to Marisol Peron, Senior Vice President of Global Communications, or Andrew Carlsen, Vice President of Investor Relations, both of whom are available for any further information needed regarding the offering.
Frequently Asked Questions
What is the total amount Genmab is raising through its notes offering?
Genmab is raising a total of $2.5 billion through the offering of senior secured and unsecured notes.
What will the proceeds from the notes be used for?
The proceeds will finance the acquisition of Merus N.V. and cover related expenses.
What are the interest rates on the secured and unsecured notes?
The secured notes carry an interest rate of 6.250%, while the unsecured notes have an interest rate of 7.250%.
Are the notes registered under the Securities Act?
No, the notes have not been registered and are offered only to qualified institutional buyers or non-U.S. persons.
How can investors obtain more information about the offering?
Investors can reach out to Genmab's Vice President of Investor Relations or consult the offering memorandum for specific details.
